Navigation Links
Simplest therapeutic regimen found less effective against HIV

Antiretroviral therapy for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy in 1996//. More recently, new drugs have been approved, offering added dosing convenience and improved safety profiles, while some previously popular drugs are being used less often as their drawbacks become better defined. Resistance testing is used more commonly in clinical practice and interactions among antiretroviral agents and with other drugs have become more complex. New government guidelines recommend against starting AIDS patients on a popular treatment combination, due to concerns that using two similar drugs can rapidly lead to treatment-resistant strains of HIV.

Therapeutic regimen that combines Videx and Viread with so-called "non-nuke" drugs like Sustiva is one of several treatment groupings that have led to the dramatic turn around against AIDS. In comparison to a litany of pills that HIV patients have to swallow to keep the virus under control, Videx and Viread, are a lot simpler to use, as they have to be taken just once a day.

However, recent studies have shown that HIV quickly grows resistant to the drugs when all three are used at once, possibly because Videx and Viread attack the disease in a like-minded fashion, and so, the Department of Health and Human Services is urging newly diagnosed patients to relinquish therapies that specifically combine these three. The new ‘Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents’ have been published, dated October 6, 2005.

Dr. Roy Gulick, an HIV specialist who helped establish the new guidelines, states that when two similar drugs are used together, they tend to mimic each other and fail. Despite falling short initially, Gulick said that the combination could still be used if other options prove unsuccessful. The new guidelines reflect the broad choice in AIDS treatment, listing the pr os and cons for each, while suggesting that doctors and patients pick a regimen that best fits their needs.

While at present there are more than 20 HIV drugs that fall under four broad categories, with an almost infinite number of combinations, the best regimens suggested are those that attack the disease from different angles.
'"/>




Related medicine news :

1. Tetanus causing toxin has therapeutic properties
2. Mice model to study bacterial therapeutic pathway
3. Hormone regimen and how recently used may determine cancer risk
4. Protective regimen for acute Graft-versus-host disease
5. Distraction therapy found very effective in postoperative patients
6. Antioxidants found in chocolates
7. Hidden influenza virus protein found
8. Scientists found ancient Human Germ Killer
9. Chewing gum found to increase brainpower
10. Ulcer causing bug found in stored food
11. Antioxidants found in chocolates
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... ... 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International ... the Center for Disease Control ( CDC ) and Infectious Diseases Society of America ... M.D. has compiled into a single volume a compelling argument that the disease does ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, ... today announced it would be offering some it’s exclusive product line to the ... quality and unique baby clothing/feeding products, will team up with AMAZON to distribute ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is linked ... LRRK2 mutation, according to a study released today at the 1st Pan American ... link between pesticides and incidence of sporadic PD through occupational exposure. This latest ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... development, education, networking and recognition opportunities as well as advocacy for the state ... Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights innovation ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Research and Markets ... Analysis & Trends - Industry Forecast to 2025" report to ... ... CAGR of around 23.8% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and ... Dry eye market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global Dry ...
(Date:2/24/2017)... -- Juan Monteverde , founder and managing partner ... securities firm headquartered at the Empire State Building in ... a class action lawsuit has been filed in the U.S. ... Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on behalf ... and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology: